» Articles » PMID: 35844799

CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering MiR-7 from Repressing IRS2-ERK-mediated CCND1 Expression

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2022 Jul 18
PMID 35844799
Authors
Affiliations
Soon will be listed here.
Abstract

Our understanding of coding gene functions in lung cancer leads to the development of multiple generations of targeted drugs. Noncoding RNAs, including circular RNAs (circRNAs), have been demonstrated to play a vital role in tumorigenesis. Uncovering the functions of circRNAs in tumorigenesis and their underlying regulatory mechanisms may shed new light on the development of novel diagnostic and therapeutic strategies for human cancer. Here we report the important role of circFAT1 in lung adenocarcinoma (LUAD) progression and the potential impact of circFAT1 on LUAD treatment. We found that circFAT1 was one of the top expressed circRNAs in A549 cells by circRNA-seq and was significantly upregulated in human LUAD tissues. Multiple cellular assays with A549 and PC9 LAUD cell lines under both gain-of-function and loss-of-function conditions demonstrated that circFAT1 promoted proliferation of LUAD cells and . At molecular level, circFAT1 sequestered miR-7 to upregulate IRS2, which in turn regulated downstream ERK1/2 phosphorylation and CCND1 expression, ultimately promoting tumor progression. In addition, we showed that DDP treatment was much more effective in circFAT1 knockdown tumor cells and in a xenograft tumor model. Our results indicate that circFAT1 promote tumorigenesis in LUAD through sequestering miR-7, consequently upregulating IRS2-ERK1/2-mediated CCND1 expression, and can be a valuable therapeutic target and an important parameter for precision treatment in LUAD patients.

Citing Articles

CircRNA circ_0015278 induces ferroptosis in lung adenocarcinoma through the miR-1228/P53 axis.

Xia L, Li G, Zhou Q, Feng Y, Ma H Oncol Res. 2025; 33(2):465-475.

PMID: 39866239 PMC: 11753987. DOI: 10.32604/or.2024.050835.


[Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance 
and Lung Cancer].

Chen X, Chen P Zhongguo Fei Ai Za Zhi. 2024; 27(10):755-762.

PMID: 39631832 PMC: 11629090. DOI: 10.3779/j.issn.1009-3419.2024.106.27.


IBPGNET: lung adenocarcinoma recurrence prediction based on neural network interpretability.

Xu Z, Liao H, Huang L, Chen Q, Lan W, Li S Brief Bioinform. 2024; 25(3).

PMID: 38557672 PMC: 10982951. DOI: 10.1093/bib/bbae080.


Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.

Heydarnia E, Dorostgou Z, Hedayati N, Mousavi V, Yahyazadeh S, Alimohammadi M Cell Commun Signal. 2024; 22(1):107.

PMID: 38341592 PMC: 10859032. DOI: 10.1186/s12964-024-01494-0.


The Relationship Between the Expression of circFAT1 and Immune Cell in Patients with Non-Small Cell Lung Cancer.

Li J, Liu Y, Zeng W, Wu Y, Ao W, Yuan X Int J Gen Med. 2023; 16:4943-4951.

PMID: 37928955 PMC: 10625319. DOI: 10.2147/IJGM.S434065.

References
1.
Torres M, Becquet D, Guillen S, Boyer B, Moreno M, Blanchard M . RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA. J Vis Exp. 2018; (134). PMC: 5933463. DOI: 10.3791/57379. View

2.
Korac P, Antica M, Matulic M . MiR-7 in Cancer Development. Biomedicines. 2021; 9(3). PMC: 8004586. DOI: 10.3390/biomedicines9030325. View

3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

4.
Wikman H, Kettunen E . Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer. Expert Rev Anticancer Ther. 2006; 6(4):515-30. DOI: 10.1586/14737140.6.4.515. View

5.
Liu M . CircFAT1 is Overexpressed in Colorectal Cancer and Suppresses Cancer Cell Proliferation, Invasion and Migration by Increasing the Maturation of miR-10a. Cancer Manag Res. 2021; 13:4309-4315. PMC: 8179739. DOI: 10.2147/CMAR.S287230. View